MARKET

SNDX

SNDX

Syndax Pharmaceuticals Inc
NASDAQ
22.30
+0.40
+1.83%
After Hours: 22.30 0 0.00% 16:02 11/28 EST
OPEN
21.89
PREV CLOSE
21.90
HIGH
22.35
LOW
21.89
VOLUME
422.70K
TURNOVER
0
52 WEEK HIGH
26.51
52 WEEK LOW
13.27
MARKET CAP
1.34B
P/E (TTM)
-101.6408
1D
5D
1M
3M
1Y
5Y
Apellis (APLS) Rises on FDA Acceptance of NDA Amendment for GA
The FDA accepts Apellis' (APLS) major amendment to the NDA for pegcetacoplan to treat geographic atrophy secondary to age-related macular degeneration. A decision is now due on Feb 26, 2023. Stock up.
Zacks · 11/21 14:44
Syndax Announces Participation at Evercore ISI Annual HealthCONx Conference
Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in a fireside chat at the Evercore ISI Annua...
PR Newswire · 11/21 12:00
Gilead (GILD) Outperforms YTD: Will It Retain the Momentum?
Biotech giant Gilead (GILD) outperforms the industry and the S&P 500 Index as its core business maintains momentum despite volatility.
Zacks · 11/18 18:45
Viatris (VTRS) Wins in Court Against AstraZeneca's Symbicort
Viatris (VTRS) and its partner win a court decision that invalidates branded drug Symbicort's patent and opens the door for them to launch their generic version of the drug.
Zacks · 11/11 15:20
Clovis (CLVS) Plummets on News of Possible Bankruptcy Filing
Clovis (CLVS) tanks following the possibility of a bankruptcy filing in the near term after recent regulatory developments impacted current revenues and the commercial potential of Rubraca.
Zacks · 11/10 15:46
--BTIG Research Adjusts Syndax Pharmaceuticals Price Target to $34 From $32, Maintains Buy Rating
--BTIG Research Adjusts Syndax Pharmaceuticals Price Target to $34 From $32, Maintains Buy Rating
MT Newswires · 11/07 14:09
--B. Riley Raises Syndax Pharmaceuticals' PT to $34 From $31, Notes Increased Confidence in Upcoming Readouts of Studies; Keeps Buy Rating
--B. Riley Raises Syndax Pharmaceuticals' PT to $34 From $31, Notes Increased Confidence in Upcoming Readouts of Studies; Keeps Buy Rating
MT Newswires · 11/07 08:08
Syndax Pharmaceuticals GAAP EPS of -$0.58 beats by $0.07; updates FY22 guidance
Seekingalpha · 11/03 20:49
More
About SNDX
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing a pipeline of cancer therapies. The Company’s lead product candidates include SNDX-5613 and SNDX-6352 (axatilimab). The Company is focused on developing SNDX-5613, targeting the binding interaction of menin with the mixed lineage leukemia 1 (MLL1), protein for the treatment of MLL-rearranged (MLLr), acute leukemias and nucleophosmin 1 (NPM1), mutant acute myeloid leukemia (AML), as well as axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. The Company’s products candidate also includes entinostat, once-weekly, oral, small molecule and Class I histone deacetylases (HDAC) inhibitor that being evaluated in the Phase III E2112 registrational clinical trial in combination with exemestane for hormone receptor positive, human epidermal growth factor receptor 2 negative and breast cancer.

Webull offers kinds of Syndax Pharmaceuticals Inc stock information, including NASDAQ:SNDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SNDX stock methods without spending real money on the virtual paper trading platform.